Inhibrx Biosciences vs Outlook Therapeutics
Outlook Therapeutics reported revenue of $1 million in fiscal 2025, about the same as Inhibrx Biosciences' $1 million in fiscal 2025. Inhibrx Biosciences had an operating margin of -10386.5%, against -4744.2% at Outlook Therapeutics. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Inhibrx Biosciences | Outlook Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | 550.0% | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 4.0% |
| Operating margin | −10,386.5% | −4,744.2% |
| Net margin | −10,773.5% | −4,416.2% |
| Free cash flow | −$130M | — |
| Free cash flow margin | −9,986.5% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.4% | 87.6% |
| Last close | $74.33 | $0.40 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $5.5 million, sold $279,015 | bought $7.9 million, sold $0 |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Inhibrx BiosciencesOutlook Therapeutics
Operating margin
Percent of revenue
Inhibrx BiosciencesOutlook Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inhibrx BiosciencesOutlook Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inhibrx Biosciences and Outlook Therapeutics pages.